Erasca licenses exclusive rights to two preclinical RAS oncology programs, ERAS-0015 and ERAS-4001.

Erasca, a clinical-stage precision oncology company, announced exclusive license agreements for two preclinical RAS programs, ERAS-0015 (potential best-in-class pan-RAS molecular glue) and ERAS-4001 (potential first-in-class pan-KRAS inhibitor). Both programs are potent oral inhibitors with potential best-in-class profiles in RASm solid tumors. Erasca's pipeline prioritization and workforce restructuring focus on high-need programs with the highest probability of success.